Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVU120 Rollover Study
2025-521673-14-00Phase 2Authorised
- Sponsor
- Ryvu Therapeutics
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of rvu120 in Nonhematologic neoplasms, myelofibrosis (MF), myelodysplastic syndrome (MDS) and 1 more (3 arms), sponsored by Ryvu Therapeutics. Primary endpoint: Incidence and severity of adverse events and serious adverse events. Planned start Aug 2025; status: authorised.
02
Drugs
rvu120
03
Conditions
Nonhematologic neoplasmsmyelofibrosis (MF)myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2025-521673-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521673-14-00.